Key Points TEMPO-1 is a randomized study expected to enroll 250 patients with second-line or later OPSCC. The trial will compare CRB-701 with the investigator’s…
September 29, 2026
September 10, 2026
Oncolytics Reports Preclinical Support for Pelareorep Plus Pan-RAS Inhibitor in Colorectal Cancer
Key Points Oncolytics Biotech reported preclinical results evaluating pelareorep with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. During the study’s initial every-other-day pelareorep…
September 04, 2026
AbbVie’s Etentamig Shows Strong Results in Phase 3 Blood Cancer Study
Key Points AbbVie’s experimental drug etentamig helped more patients with hard-to-treat multiple myeloma respond to treatment than standard therapies. The drug cut the risk of…
Key Points BriaCell Therapeutics Corp. received FDA clearance to begin a clinical study of Bria-PROS in prostate cancer. The company is developing Bria-PROS as a…
July 09, 2026
Delcath Systems Starts Phase 2 HEPZATO Trial in Liver-Dominant Metastatic Breast Cancer
Delcath Systems Inc. (NASDAQ: DCTH) has dosed the first patient in its Phase 2 clinical trial evaluating HEPZATO in people with liver-dominant metastatic breast cancer…
Parabilis Medicines’ (NASDAQ: PBLS) Wall Street debut just reset the bar for biotech IPOs, with the cancer‑focused peptide company raising 670 million dollars in an…
Roche Holding AG (OTC: RHHBY) is making a major push deeper into targeted protein degradation, signing a deal worth up to 2.3 billion dollars with…
At EHA 2026 this month, Legend Biotech (NASDAQ: LEGN) is presenting early data on LB2501, an in vivo CAR-T therapy that builds CAR-T cells inside…
Eli Lilly and Company (NYSE: LLY) announced that its targeted therapy Retevmo (selpercatinib) cut the risk of disease recurrence or death by 83 percent versus placebo in patients with…
Aptevo Therapeutics Inc. (NASDAQ: APVO) and Niowave Inc. are forming a 50/50 partnership to develop up to three radiopharmaceutical cancer drugs, giving both companies a…
Alpha Tau Medical (NASDAQ: DRTS) has hit a key milestone in its pancreatic cancer program, successfully treating the first pancreatic cancer patient in Europe with its…